BIOMAT Database Logo BIOMAT Database Logo

Uncoupling DAPK1 from NMDA receptor GluN2B subunit exerts rapid antidepressant-like effects. 2018

S-X Li, and Y Han, and L-Z Xu, and K Yuan, and R-X Zhang, and C-Y Sun, and D-F Xu, and M Yuan, and J-H Deng, and S-Q Meng, and X-J Gao, and Q Wen, and L-J Liu, and W-L Zhu, and Y-X Xue, and M Zhao, and J Shi, and L Lu
National Institute on Drug Dependence, Peking University, Beijing, China.

Several preclinical studies have reported the rapid antidepressant effects of N-methyl-D-aspartate receptor (NMDAR) antagonists, although the underlying mechanisms are still unclear. Death-associated protein kinase 1 (DAPK1) couples GluN2B subunits at extrasynaptic sites to regulate NMDAR channel conductance. In the present study, we found that chronic unpredictable stress (CUS) induced extracellular glutamate accumulation, accompanied by an increase in the DAPK1-NMDAR interaction, the high expression of DAPK1 and phosphorylated GluN2B at Ser1303, a decrease in phosphorylated DAPK1 at Ser308 and synaptic protein deficits in the rat medial prefrontal cortex (mPFC). CUS also enhanced GluN2B-mediated NMDA currents and extrasynaptic responses that were induced by bursts of high-frequency stimulation, which may be associated with the loss of astrocytes and low expression of glutamate transporter-1 (GLT-1). The blockade of GLT-1 in the mPFC was sufficient to induce depressive-like behavior and cause similar molecular changes. Selective GluN2B antagonist, DAPK1 knockdown by adeno-associated virus-mediated short-hairpin RNA or a pharmacological inhibitor, and the uncoupling of DAPK1 from the NMDAR GluN2B subunit produced rapid antidepressant-like effects and reversed CUS-induced alterations in the mPFC. The inhibition of DAPK1 and its interaction with GluN2B subunit in the mPFC also rescued CUS-induced depressive-like behavior 7 days after treatment. A selective GluN2B antagonist did not have rewarding effects in the conditioned place preference paradigm. Altogether, our findings suggest that the DAPK1 interaction with the NMDAR GluN2B subunit acts as a critical component in the pathophysiology of depression and is a potential target for new antidepressant treatments.

UI MeSH Term Description Entries
D008297 Male Males
D010766 Phosphorylation The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. Phosphorylations
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D003863 Depression Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders. Depressive Symptoms,Emotional Depression,Depression, Emotional,Depressive Symptom,Symptom, Depressive
D003866 Depressive Disorder An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent. Depression, Endogenous,Depression, Neurotic,Depression, Unipolar,Depressive Syndrome,Melancholia,Neurosis, Depressive,Unipolar Depression,Depressions, Endogenous,Depressions, Neurotic,Depressions, Unipolar,Depressive Disorders,Depressive Neuroses,Depressive Neurosis,Depressive Syndromes,Disorder, Depressive,Disorders, Depressive,Endogenous Depression,Endogenous Depressions,Melancholias,Neuroses, Depressive,Neurotic Depression,Neurotic Depressions,Syndrome, Depressive,Syndromes, Depressive,Unipolar Depressions
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000928 Antidepressive Agents Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems. Antidepressant,Antidepressant Drug,Antidepressant Medication,Antidepressants,Antidepressive Agent,Thymoanaleptic,Thymoanaleptics,Thymoleptic,Thymoleptics,Antidepressant Drugs,Agent, Antidepressive,Drug, Antidepressant,Medication, Antidepressant
D013315 Stress, Psychological Stress wherein emotional factors predominate. Cumulative Stress, Psychological,Emotional Stress,Individual Stressors,Life Stress,Psychological Cumulative Stress,Psychological Stress Experience,Psychological Stress Overload,Psychologically Stressful Conditions,Stress Experience, Psychological,Stress Measurement, Psychological,Stress Overload, Psychological,Stress Processes, Psychological,Stress, Emotional,Stressful Conditions, Psychological,Psychological Stress,Stress, Psychologic,Stressor, Psychological,Condition, Psychological Stressful,Condition, Psychologically Stressful,Conditions, Psychologically Stressful,Cumulative Stresses, Psychological,Experience, Psychological Stress,Individual Stressor,Life Stresses,Measurement, Psychological Stress,Overload, Psychological Stress,Psychologic Stress,Psychological Cumulative Stresses,Psychological Stress Experiences,Psychological Stress Measurement,Psychological Stress Measurements,Psychological Stress Overloads,Psychological Stress Processe,Psychological Stress Processes,Psychological Stresses,Psychological Stressful Condition,Psychological Stressful Conditions,Psychological Stressor,Psychological Stressors,Psychologically Stressful Condition,Stress Experiences, Psychological,Stress Processe, Psychological,Stress, Life,Stress, Psychological Cumulative,Stressful Condition, Psychological,Stressful Condition, Psychologically,Stressor, Individual
D015398 Signal Transduction The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway. Cell Signaling,Receptor-Mediated Signal Transduction,Signal Pathways,Receptor Mediated Signal Transduction,Signal Transduction Pathways,Signal Transduction Systems,Pathway, Signal,Pathway, Signal Transduction,Pathways, Signal,Pathways, Signal Transduction,Receptor-Mediated Signal Transductions,Signal Pathway,Signal Transduction Pathway,Signal Transduction System,Signal Transduction, Receptor-Mediated,Signal Transductions,Signal Transductions, Receptor-Mediated,System, Signal Transduction,Systems, Signal Transduction,Transduction, Signal,Transductions, Signal

Related Publications

S-X Li, and Y Han, and L-Z Xu, and K Yuan, and R-X Zhang, and C-Y Sun, and D-F Xu, and M Yuan, and J-H Deng, and S-Q Meng, and X-J Gao, and Q Wen, and L-J Liu, and W-L Zhu, and Y-X Xue, and M Zhao, and J Shi, and L Lu
Dynamic regulation of phosphorylation of NMDA receptor GluN2B subunit tyrosine residues mediates ketamine rapid antidepressant effects.
May 2024, Pharmacological research,
S-X Li, and Y Han, and L-Z Xu, and K Yuan, and R-X Zhang, and C-Y Sun, and D-F Xu, and M Yuan, and J-H Deng, and S-Q Meng, and X-J Gao, and Q Wen, and L-J Liu, and W-L Zhu, and Y-X Xue, and M Zhao, and J Shi, and L Lu
Uncoupling the dopamine D1-D2 receptor complex exerts antidepressant-like effects.
December 2010, Nature medicine,
S-X Li, and Y Han, and L-Z Xu, and K Yuan, and R-X Zhang, and C-Y Sun, and D-F Xu, and M Yuan, and J-H Deng, and S-Q Meng, and X-J Gao, and Q Wen, and L-J Liu, and W-L Zhu, and Y-X Xue, and M Zhao, and J Shi, and L Lu
Pyrazole Inhibitors of GluN2B NMDA Receptor Subunit.
December 2016, ACS medicinal chemistry letters,
S-X Li, and Y Han, and L-Z Xu, and K Yuan, and R-X Zhang, and C-Y Sun, and D-F Xu, and M Yuan, and J-H Deng, and S-Q Meng, and X-J Gao, and Q Wen, and L-J Liu, and W-L Zhu, and Y-X Xue, and M Zhao, and J Shi, and L Lu
NMDA receptor subunits and associated signaling molecules mediating antidepressant-related effects of NMDA-GluN2B antagonism.
January 2015, Behavioural brain research,
S-X Li, and Y Han, and L-Z Xu, and K Yuan, and R-X Zhang, and C-Y Sun, and D-F Xu, and M Yuan, and J-H Deng, and S-Q Meng, and X-J Gao, and Q Wen, and L-J Liu, and W-L Zhu, and Y-X Xue, and M Zhao, and J Shi, and L Lu
Positive modulation of NMDA receptors by AGN-241751 exerts rapid antidepressant-like effects via excitatory neurons.
March 2021, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,
S-X Li, and Y Han, and L-Z Xu, and K Yuan, and R-X Zhang, and C-Y Sun, and D-F Xu, and M Yuan, and J-H Deng, and S-Q Meng, and X-J Gao, and Q Wen, and L-J Liu, and W-L Zhu, and Y-X Xue, and M Zhao, and J Shi, and L Lu
Pro-death NMDA receptor signaling is promoted by the GluN2B C-terminus independently of Dapk1.
July 2017, eLife,
S-X Li, and Y Han, and L-Z Xu, and K Yuan, and R-X Zhang, and C-Y Sun, and D-F Xu, and M Yuan, and J-H Deng, and S-Q Meng, and X-J Gao, and Q Wen, and L-J Liu, and W-L Zhu, and Y-X Xue, and M Zhao, and J Shi, and L Lu
GluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamine.
October 2014, eLife,
S-X Li, and Y Han, and L-Z Xu, and K Yuan, and R-X Zhang, and C-Y Sun, and D-F Xu, and M Yuan, and J-H Deng, and S-Q Meng, and X-J Gao, and Q Wen, and L-J Liu, and W-L Zhu, and Y-X Xue, and M Zhao, and J Shi, and L Lu
Genetic inactivation of the NMDA receptor NR2A subunit has anxiolytic- and antidepressant-like effects in mice.
November 2006, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,
S-X Li, and Y Han, and L-Z Xu, and K Yuan, and R-X Zhang, and C-Y Sun, and D-F Xu, and M Yuan, and J-H Deng, and S-Q Meng, and X-J Gao, and Q Wen, and L-J Liu, and W-L Zhu, and Y-X Xue, and M Zhao, and J Shi, and L Lu
A Negative Allosteric Modulator for α5 Subunit-Containing GABA Receptors Exerts a Rapid and Persistent Antidepressant-Like Action without the Side Effects of the NMDA Receptor Antagonist Ketamine in Mice.
January 2017, eNeuro,
S-X Li, and Y Han, and L-Z Xu, and K Yuan, and R-X Zhang, and C-Y Sun, and D-F Xu, and M Yuan, and J-H Deng, and S-Q Meng, and X-J Gao, and Q Wen, and L-J Liu, and W-L Zhu, and Y-X Xue, and M Zhao, and J Shi, and L Lu
Intrahippocampal injection of a selective blocker of NMDA receptors containing the GluN2B subunit, Ro25-6981, increases glutamate neurotransmission and induces antidepressant-like effects.
December 2023, Fundamental & clinical pharmacology,
Copied contents to your clipboard!